Arcturus Therapeutics Holdings (ARCT) Consolidated Net Income (2018 - 2026)

Arcturus Therapeutics Holdings (ARCT) has 9 years of Consolidated Net Income data on file, last reported at -$56.6 million in Q1 2026.

• Quarterly Consolidated Net Income fell 302.2% year-over-year to -$56.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$108.3 million (down 58.92% YoY) and the FY2025 annual result came in at -$65.8 million, up 18.74% from the prior year.
• Consolidated Net Income fell to -$56.6 million in Q1 2026, from -$29.1 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of $118.6 million in Q4 2022 to a low of -$56.6 million in Q1 2026.
• A 5-year average of -$13.1 million and a median of -$17.2 million in 2024 frame the typical range for Consolidated Net Income.
• Annual changes were most pronounced in 2022 — Consolidated Net Income soared 413.74% — and 2026, when it slumped 302.2%.
• Tracing ARCT's Consolidated Net Income over 5 years: stood at $118.6 million in 2022, then slumped by 109.87% to -$11.7 million in 2023, then sank by 156.3% to -$30.0 million in 2024, then gained by 3.13% to -$29.1 million in 2025, then plunged by 94.78% to -$56.6 million in 2026.
• The last three Consolidated Net Income figures came in at -$56.6 million (Q1 2026), -$29.1 million (Q4 2025), and -$13.4 million (Q3 2025), per Business Quant data.